⌘+K

Update Note

From reset to recovery - Q3 2025/26 preview

Erik Hultgård

Arvid Necander

2026-01-27

07:11 CET

We have been cautious on the outlook since the September profit warning, during which time the share price has de-rated materially. With Q2 now behind us and visibility expected to improve from Q3, we are turning more constructive on the business outlook, as we see scope for a recovery in growth and margins as operational conditions stabilise.

Through the trough – growth set to re-accelerate. We forecast 27% Y/Y sales growth in Q3, driven by restocking in both niche generics and branded products. With sales recovery and limited opex growth Q/Q, we expect margins to recover, forecasting a 41% gross margin and a 15% EBIT margin, up from 4% in Q2 2025/26. We believe branded products have reached an inflection point, supported by recent and upcoming launches (including Mellozzan in the UK and Germany, and Memprex in France and BeNeLux), where penetration remains at an early stage relative to longer-term potential.

Stage set for strong 2026/27. Stage set for strong 2026/27. Our EBIT forecasts are broadly unchanged for 2025/26 (+1%), but reduced for 2026/27 (-7%) and 2027/28 (-4%), reflecting a more cautious view on the pace of earnings normalisation after supplier disruptions and initial restocking. With more normalised inventory levels entering 2026/27, materially easier comparisons and a strong pipeline, we forecast 37% Y/Y sales growth in 2026/27, which should support a significant recovery in earnings and margins.

Fair value range of SEK70–90 unchanged. Having been cautious on the prospects as the investment case reset, we are now more constructive on the business outlook as confidence in execution rebuilds. We believe the 2026/27 setup offers scope for renewed earnings momentum, while Memprex remains under-recognised by investors. We also expect initial read-throughs on market potential in Germany and the Netherlands following EQL’s first steps to establish a presence, and note that the EU–India free trade agreement appears close to completion, with a formal announcement likely at the EU–India summit on 27 January 2026.

Sweden

Healthcare

Latest share price

SEK

23.0

-5.17%

18 Nov 2026 15:26 CET

Fair value range

SEK

35.0

—

55.0

30 Oct 2026

Market cap

SEK

678

m

Key stats

Year

2026e

EPS

0.30

EPS (Adj.)

1.48

Sales Growth

17.51%

EPS Growth (Adj.)

71.52%

P/E

77.0

P/E (Adj.)

15.5

EV/EBITA

26.7

EV/EBITDA

15.2

Learn more

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB